Analysis of regional data indicates significant year-over-year growth in hormone-related treatments and related services.
By yourNEWS Media Newsroom
A newly released analysis from the Concerned Women for America Legislative Action Committee reports a substantial rise in gender-related medical services provided by Planned Parenthood affiliates during 2025, based on a review of regional disclosures.
According to the report, which compiles data from multiple affiliate regions, gender-related services—including clinical visits, treatments, and other related activities—increased by more than 40 percent over the previous year. The analysis draws from regional reporting to provide a broader dataset than the organization’s most recent annual report released this month.
The findings indicate that approximately 14 regional affiliates consistently reported data on these services, each showing year-over-year growth. In several regions, the increases were more pronounced. Facilities affiliated with Planned Parenthood of Greater Ohio recorded a 50 percent rise in gender-related services in 2025, following increases of 200 percent and 544 percent in prior reporting periods. Other regions, including Planned Parenthood of Greater Washington and Northern Idaho, more than doubled their reported activity since 2022–2023, while Planned Parenthood of the Great Plains reported a 90 percent increase, and Planned Parenthood of Western Pennsylvania also recorded a doubling of services over the same timeframe.
Macy Petty, a legislative strategist with the organization behind the report, stated in remarks to the Daily Wire that increases have continued over multiple years. Penny Nance, president of the organization, said the findings raise questions about federal funding policies tied to the organization.
The report contrasts its findings with publicly available national-level disclosures from Planned Parenthood, which include limited references to such services. In its latest report, the organization notes ongoing research examining the effects of state-level restrictions on gender-related medical care while including “transgender services” within a broader category labeled “Other Procedures,” totaling 50,411.
Planned Parenthood publicly describes its services on its website, where it advertises itself as offering hormone-related treatments for individuals identifying as transgender or nonbinary, including medications such as estrogen, testosterone, anti-androgens, and puberty blockers.
Historical data referenced in prior reporting indicates that as of its 2022–2023 annual report, 45 affiliates offered hormone-based treatments, while a previous report noted participation by 30 affiliates in dozens of medical studies.
The report also references broader scientific and policy discussions surrounding gender-related medical interventions. A review cited within the analysis raises concerns about potential risks associated with such treatments, particularly among younger populations.
In the United Kingdom, the National Health Service commissioned an independent evaluation known as the Cass Review, which examined evidence related to pediatric gender medicine. The review concluded that existing research in the field shows limitations in quality and consistency, emphasizing the need for caution in clinical decision-making.
Additional international research has explored mental health outcomes among individuals undergoing gender-related medical interventions. A Finnish study examining individuals under age 23 found higher levels of psychiatric conditions both before and after treatment, with continued need for care over time.
Accounts from individuals who have reversed prior transitions have also been documented, including reports of physical and psychological challenges following medical procedures. Some of these perspectives are detailed in accounts from individuals and public events focused on detransition experiences, as well as personal testimonies describing long-term outcomes.
The report further references a 2022 exposé involving a university medical center, in which a physician discussed financial aspects associated with surgical procedures.
The findings contribute to ongoing national and international discussions regarding medical standards, reporting practices, and policy considerations surrounding gender-related healthcare services.
Original article
Comments